ClinicalTrials.gg
CompletedNCT05891236Updated Jun 12, 2026Results posted

Safety, Tolerability, Pharmacokinetics and Protective Efficacy of MAM01 in Healthy Adults

A Phase 1 interventional study of MAM01 1.5 mg/kg and Placebo in Malaria, sponsored by Gates Medical Research Institute. Completed at 1 site in United States. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-12.

Sponsored by Gates Medical Research Institute · Phase 1, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
63
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 105 studies in Malaria with a site in United States — 9 open to participants now, 10 under way, none of them phase 3. Malaria · United States.

Enrollment
34th of 89
63 · median 45
Started
2023
with 2 others
Phase 1
62 of 105
1 open now
Registered
97th of 105
by date

Among the 105 studies in Malaria with a site in United States, this one is the 34th largest by enrollment of the 89 interventional ones that give a count, is one of 3 that started in 2023, is one of 62 in phase 1, and was the 97th registered.

Malaria

1,187 studies on the registry are indexed under Malaria; 80 are open to participants now.

Browse Malaria studies →

Open to participants now

9 of the 105 studies in Malaria with a site in United States are open now. Recruiting first, the newest first:

4 more — sign in →

All 9 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 51 Malaria studies recruiting now, 15 (29%) set no upper age limit and 33 (65%) stop at 75 or younger; 37 take children under 18; 31 take healthy volunteers.

This study: 18 Years to 50 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 105 studies in Malaria with a site in United States, or all of them as a file.
02

Study summary

This is a First-in-Human (FiH), randomized, two-part, dose-escalation trial of MAM01 monoclonal antibody (mAb) targeting the Plasmodium falciparum (Pf) Circumsporozoite Protein (CSP). This study will evaluate the safety, tolerability, pharmacokinetics (PK), and protective efficacy of MAM01, as well as safety and PK of repeat subcutaneous (SC) dosing. Part A will have a double-blind, placebo-controlled design. Part B will randomize participants to one of three open-label MAM01 dose groups; a separate non-randomized group will be enrolled to include participants who will receive no treatment and act as infectivity controls.

03

Conditions studied

  • Malaria

Browse trials for

Keywords

  • Healthy volunteers
  • MAM01 monoclonal antibody
  • First-in-Human
  • Dose-escalation
  • Single ascending dose
  • Multiple ascending dose
  • Recruiting
  • Malaria vaccine
  • Mosquito
  • Gates
  • Prevention
  • Phase 1
  • Nonprofit
04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants who are healthy as determined by medical evaluation including medical history, physical examination and laboratory tests
  • (BMI) 18 to 30 kilograms per square meter (kg/m\^2) (inclusive) to a maximum of 220 pounds
  • Both males and females are eligible to participate as per the following:

    a. Female participants physically capable of pregnancy, have at least one negative pregnancy test during Screening, on the day of enrollment, prior to product (IP) administration, prior to CHM and at the start of antimalarial treatment, and who agree to use effective to avoid pregnancy from 28 days before enrollment through 10 months after last administration of investigational product are eligible to participate.

  • Capable of giving signed which includes compliance with the requirements and restrictions listed in the Informed Consent Form (ICF) and the trial protocol, and completion of a test of understanding if he/she may participate in the CHMI procedure
  • Reported completion of primary Coronavirus Disease (COVID) vaccine series is documented

Exclusion criteria

Exclusion criteria:

  • Acute illness or fever ≥99.5°Fahrenheit (F) (or ≥37.5 degrees Celsius) on day of dosing
  • Women who are pregnant or breastfeeding
  • Evidence and/or history of medical condition(s) as judged by the Investigator, including , diabetes mellitus, and unstable or uncontrolled hypertension
  • A 5-year cardiovascular risk of ≥10% using the Gaziano nomogram
  • History of any disease or immune deficiency or other impairment to the immune system, including but not limited to (HIV), autoimmune conditions or therapy
  • Participation in an interventional clinical trial and/or receipt of any drug within 180 days prior to administration of trial drug on Day 0
  • Anticipated use of medications known to cause drug reactions with chloroquine or atovaquone-proguanil (Malarone) such as cimetidine, metoclopramide, antacids, and kaolin

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Care provider)
Enrollment
63 participants (actual)

Study arms

  • Experimental
    Part A: Single Ascending Dose (SAD): Dose escalation cohort 1: MAM01 and placebo Intravenous (IV)

    2 sentinel participants will be randomized in a 1:1 ratio to receive MAM01 1.5 milligrams per kilogram (mg/kg) IV or placebo. Following at least a 24-hour safety review period, the 6 remaining participants of Cohort 1 will be randomized in a 5:1 ratio to receive MAM01 1.5 mg/kg IV or placebo.

    Biological: MAM01 1.5 mg/kg · Biological: Placebo

  • Experimental
    Part A: SAD dosing: Dose escalation Cohort 2: MAM01 and placebo SC

    7 participants will be randomly assigned in a 6:1 ratio to receive MAM01 5 mg/kg SC or placebo

    Biological: MAM01 5 mg/kg · Biological: Placebo

  • Experimental
    Part A: SAD dosing: Dose escalation Cohort 3: MAM01 and placebo IV

    7 participants will be randomly assigned in a 6:1 ratio to receive MAM01 5 mg/kg IV or placebo.

    Biological: Placebo · Biological: MAM01 5 mg/kg

  • Experimental
    Part A: SAD dosing: Dose escalation Cohort 4: MAM01 and placebo IV

    8 participants will be randomly assigned in a 6:2 ratio to receive MAM01 10 mg/kg IV or placebo.

    Biological: Placebo · Biological: MAM01 10 mg/kg

  • Experimental
    Part A: SAD dosing: Dose escalation Cohort 5: MAM01 and placebo IV

    7 participants will be randomly assigned in a 6:1 ratio to receive MAM01 40 mg/kg IV or placebo

    Biological: Placebo · Biological: MAM01 40 mg/kg

  • Experimental
    Part A: Multiple Ascending Dose (MAD) (Repeat dosing): MAM01

    Participants from Cohort 2 and from Cohort 3 will receive 5 mg/kg MAM01 SC.

    Biological: MAM01 5 mg/kg

  • Experimental
    Part B: Dose Expansion Cohort 6: Group 1: MAM01

    6 participants will receive a 450 mg SC dose of MAM01. The dose was selected by applying a PK-pharmacodynamic (PD) model from the Part A data to estimate a (data-driven) protection threshold at Controlled Human Malaria Infection (CHMI).

    Biological: MAM01 450 mg

  • Experimental
    Part B: Dose Expansion Cohort 6: Group 2: MAM01

    8 participants will receive a 600 mg SC dose of MAM01. The dose was selected by applying a PK-PD model from the Part A data to estimate a (data-driven) protection threshold at CHMI

    Biological: MAM01 600 mg

  • Experimental
    Part B: Dose Expansion Cohort 6: Group 3: MAM01

    8 participants will receive 900 mg SC dose of MAM01. The dose was selected by applying a PK-PD model from the Part A data to estimate a (data-driven) protection threshold at CHMI.

    Biological: MAM01 900 mg

  • Experimental
    Internal Infectivity Controls

    6 participants will be enrolled into a non-randomized group prior to CHMI. These participants will receive no treatment and act as infectivity controls

    Other: Control

Interventions

  • BiologicalMAM01 1.5 mg/kg

    1.5 mg/kg MAM01 will be administered via IV route.

  • BiologicalPlacebo

    Placebo will be administered via IV route.

  • BiologicalMAM01 5 mg/kg

    5 mg/kg MAM01 will be administered via SC route.

  • BiologicalMAM01 10 mg/kg

    10 mg/kg MAM01 will be administered via IV route.

  • BiologicalMAM01 40 mg/kg

    40 mg/kg MAM01 will be administered via IV route.

  • BiologicalMAM01 450 mg

    MAM01 will be administered via SC route.

  • BiologicalPlacebo

    Placebo will be administered via SC route.

  • BiologicalMAM01 5 mg/kg

    5 mg/kg MAM01 will be administered via IV route.

  • OtherControl

    No drug or placebo will be administered.

  • BiologicalMAM01 600 mg

    MAM01 will be administered via SC route.

  • BiologicalMAM01 900 mg

    MAM01 will be administered via SC route.

06

What researchers measure

Primary outcomes

  1. Number of Participants Reporting Solicited Adverse Events (AEs) in the Subcutaneous Cohorts

    Solicited AEs were defined events participants were specifically asked about, which were recorded by participants in the memory aid card. Solicited AES included local injection site AEs (pain, redness, swelling, itching and bruising) and systemic AEs (fever, chills, headache, fatigue, nausea, muscle pain and joint pain). A Solicited AE does not necessarily have a causal relationship with the intervention.

    Time frame: Day 1 to Day 7 post dose

  2. Number of Participants Reporting Unsolicited Adverse Events

    In this study an unsolicited AE is any AE not captured as a solicited AE in the Memory Aid Card between Day 0 and Day 7 after MAM01 dosing, and all AEs occurring after Day 7 post dose were collected as Unsolicited AEs.

    Time frame: Through Day 28 post dose

  3. Number of Participants Reporting Serious Adverse Events (SAEs) Including Suspected Unexpected Serious Adverse Reactions (SUSARs) and Adverse Events Special Interest (AESIs)

    A SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect or is a medically significant / important event or reaction. SUSARs are AEs reported for a clinical trial participant, which is assessed by the Sponsor and or study investigator as being unexpected, serious and as having a reasonable possibility of a causal relationship with the study drug. AESIs are adverse events that the Sponsor wants to monitor closely and which require expedited reporting.

    Time frame: Up to Day 168

  4. Number of Participants Who Received 2 Doses Reporting SUSARs, SAEs and AESIs

    A SAE is defined as any untoward medical occurrence that, at any dose: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect or is a medically significant / important event or reaction. SUSARs are AEs reported for a clinical trial participant, which is assessed by the Sponsor and or study investigator as being unexpected, serious and as having a reasonable possibility of a causal relationship with the study drug. AESIs are adverse events that the Sponsor wants to monitor closely and which require expedited reporting.

    Time frame: Through Day 336

  5. Number of Participants With Clinically Significant Changes in Serum Chemistry Parameters

    Blood samples were collected for the assessment of alanine transaminase, aspartate aminotransferase, alkaline phosphatase, total carbon-dioxide (CO2), chloride, total bilirubin, creatinine, blood urea nitrogen, glucose, albumin, total protein, sodium and potassium.

    Time frame: Through Day 336

  6. Number of Participants With Clinically Significant Changes in Hematology Parameters

    Blood samples were collected for the assessment of complete blood count (CBC) including hemoglobin, platelet count, and white blood cell counts, and differential to include the absolute counts for neutrophils, lymphocytes, eosinophils, and monocytes.

    Time frame: Through Day 336

Secondary outcomes

  1. Maximal Observed Concentration (Cmax) Following Single Dose of MAM01

    Serum from venous blood samples was collected for measurement of MAM01 pharmacokinetics.

    Time frame: Pre-dose, Day 0: end of infusion (EOI), 1, 3 and 6 hours; Day 1: 24 hours; Day 2: 48 hours; Days 7, 14, 28, 42, 56, 70, 84, 98, 112, 140, 168, 224 and 280 post-dose

  2. Cmax Following Repeat Dosing of MAM01

    Serum from venous blood samples was collected for measurement of MAM01 pharmacokinetics.

    Time frame: Pre-dose, Day 0: end of infusion (EOI), 1, 3 and 6 hours, Day 1: 24 hours, Day 2: 48 hours, Days 7, 14, 28, 42, 56, 70, 84, 98, 112, 140, 168, 224 and 280 post-dose

  3. Area Under the Curve (AUC) From Time=0 to the Last Measurable Concentration (AUC0-t) Following Single Dose of MAM01

    Serum from venous blood samples was collected for measurement of MAM01 pharmacokinetics.

    Time frame: Pre-dose, Day 0: end of infusion (EOI), 1, 3 and 6 hours; Day 1: 24 hours; Day 2: 48 hours; Days 7, 14, 28, 42, 56, 70, 84, 98, 112, 140, 168, 224 and 280 post-dose

  4. AUC (0-t) Following Repeat Dosing of MAM01

    Serum from venous blood samples was collected for measurement of MAM01 pharmacokinetics.

    Time frame: Pre-dose, Day 0: end of infusion (EOI), 1, 3 and 6 hours; Day 1: 24 hours; Day 2: 48 hours; Days 7, 14, 28, 42, 56, 70, 84, 98, 112, 140, 168, 224 and 280 post-dose

  5. Partial AUC's Time= 0 to the CHMI Challenge (AUC0-CHMI) of MAM01

    Serum from venous blood samples was collected for measurement of MAM01 pharmacokinetics.

    Time frame: Pre-dose, Day 0: end of infusion (EOI), 1, 3 and 6 hours; Day 1: 24 hours; Day 2: 48 hours; Days 7, 14, 28, 42, 56, 70, 84, 98, 112, 140, 168, 224 and 280 post-dose

  6. Concentration at the Time of CHMI (CCHMI) of MAM01

    Serum from venous blood samples was collected for measurement of MAM01 pharmacokinetics.

    Time frame: Pre-dose, Day 0: end of infusion (EOI), 1, 3 and 6 hours; Day 1: 24 hours; Day 2: 48 hours; Days 7, 14, 28, 42, 56, 70, 84, 98, 112, 140, 168, 224 and 280 post-dose

  7. Blood Terminal Elimination Rate Constant (λz) of MAM01

    Serum from venous blood samples was collected for measurement of MAM01 pharmacokinetics.

    Time frame: Pre-dose, Day 0: end of infusion (EOI), 1, 3 and 6 hours; Day 1: 24 hours; Day 2: 48 hours; Days 7, 14, 28, 42, 56, 70, 84, 98, 112, 140, 168, 224 and 280 post-dose

  8. Terminal Half Life (t1/2) Following Single Dose of MAM01

    Serum from venous blood samples was collected for measurement of MAM01 pharmacokinetics.

    Time frame: Time Frame: Pre-dose, Day 0: end of infusion (EOI), 1, 3 and 6 hours; Day 1: 24 hours; Day 2: 48 hours; Days 7, 14, 28, 42, 56, 70, 84, 98, 112, 140, 168, 224 and 280 post-dose

  9. t1/2 Following Repeat Dosing of MAM01

    Serum from venous blood samples was collected for measurement of MAM01 pharmacokinetics.

    Time frame: Pre-dose, Day 0: end of infusion (EOI), 1, 3 and 6 hours; Day 1: 24 hours; Day 2: 48 hours; Days 7, 14, 28, 42, 56, 70, 84, 98, 112, 140, 168, 224 and 280 post-dose

  10. AUC From Time=0 Extrapolated to Infinity (AUC0-infinity) of MAM01

    Serum from venous blood samples was collected for measurement of MAM01 pharmacokinetics.

    Time frame: Pre-dose, Day 0: end of infusion (EOI), 1, 3 and 6 hours; Day 1: 24 hours; Day 2: 48 hours; Days 7, 14, 28, 42, 56, 70, 84, 98, 112, 140, 168, 224 and 280 post-dose

  11. Absolute Bioavailability of SC Formulation Following Repeated Dosing of MAM01

    Serum from venous blood samples was collected for measurement of MAM01 pharmacokinetics.

    Time frame: Pre-dose, Day 0: end of infusion (EOI), 1, 3 and 6 hours; Day 1: 24 hours; Day 2: 48 hours; Days 7, 14, 28, 42, 56, 70, 84, 98, 112, 140, 168, 224, 280 and 378 post-dose

  12. Accumulation Ratio (AUC0-168) Following Repeated Doses of MAM01

    Serum from venous blood samples was collected for measurement of MAM01 pharmacokinetics. The accumulation ratio was calculated as the ratio of AUC (0-168) (post first dose) to AUC (210-378) (post redose).

    Time frame: Pre-dose, Day 0: end of infusion (EOI), 1, 3 and 6 hours; Day 1: 24 hours; Day 2: 48 hours; Days 7, 14, 28, 42, 56, 70, 84, 98, 112, 140 and 168 post-dose

  13. Number of Participants With Confirmed Pf Infection Assessed by Quantitative Polymerase Chain Reaction Assay (qRT-PCR) After CHMI

    The characterization of protective efficacy against Pf following CHMI challenge, was assessed by evaluating the presence or absence of Pf infection as determined by qRT-PCR after CHMI (planned through 4 weeks post-CHMI) and evaluating the time to parasitemia after CHMI in each cohort.

    Time frame: Up to Day 27 post-CHMI

  14. Time to Parasitemia After CHMI

    Parasitemia was assessed by qRT-PCR up to Day 27 following CHMI. In addition, a thick blood smear was prepared for microscopic analysis, which was examined only once the first qRT-PCR sample tested positive. Daily parasitemia monitoring continued until the participant had a confirmed initial positive qRT-PCR. The first positive qRT-PCR triggered either a second PCR test or microscopic analysis of the blood smear. Once two positive results were obtained, rescue therapy was initiated.

    Time frame: Up to Day 27 post-CHMI

  15. Cohorts 1, 4 and 5: Numbers of Participants With Seroconversion

    The formation of ADAs (immunogenicity) following MAM01 SC and/or IV administration) was evaluated by measuring titers of ADA to MAM01 to last study visit for all participants. Capillary blood samples and selected serum samples were collected on volumetric absorptive micro-sampling (VAMS) devices at timepoints.

    Time frame: Up to Day 280

  16. Cohorts 2 and 3: Numbers of Participants Receiving 2 Doses With Seroconversion

    The formation of ADAs (immunogenicity) following MAM01 SC and/or IV administration) was evaluated by measuring titers of ADA to MAM01 to last study visit for all participants. Capillary blood samples and selected serum samples were collected on volumetric absorptive micro-sampling (VAMS) devices at timepoints.

    Time frame: Up to Day 378

  17. Cohort 6: Numbers of Participants With Seroconversion

    The formation of ADAs (immunogenicity) following MAM01 SC and/or IV administration) was evaluated by measuring titers of ADA to MAM01 to last study visit for all participants. Capillary blood samples and selected serum samples were collected on volumetric absorptive micro-sampling (VAMS) devices at timepoints.

    Time frame: Up to Day 84

07

Results

Posted Jun 12, 2026

Participant flow

A two-part randomized, dose-escalation study to assess anti-malarial human monoclonal antibody MAM01 in healthy, malaria-naïve adults. Part A: double-blind, placebo-controlled, single-ascending dose (SAD) study, while Part B: dose expansion was open-label. The study evaluated safety, tolerability, pharmacokinetics, and protective efficacy of MAM01 against controlled human malaria infection (CHMI) with Plasmodium falciparum NF54. Safety and PK of repeat subcutaneous dosing were also evaluated.

Participant flow — Overall Study
MilestonePart A (SAD Cohort 1): MAM01 1.5 mg/kg IVPart A (SAD Cohort 2): MAM01 5 mg/kg SC (Repeat Dose 5 mg/kg SC)Part A (SAD Cohort 3): MAM01 5 mg/kg IV (Repeat Dose 5 mg/kg SC)Part A (SAD Cohort 4): MAM01 10 mg/kg IVPart A (SAD Cohort 5): MAM01 40 mg/kg IVPart A: PlaceboPart A: Infectivity ControlsPart B (Cohort 6, Group 1): MAM01 450 mg/kg SCPart B (Cohort 6, Group 2): MAM01 600 mg/kg SCPart B (Cohort 6, Group 3): MAM01 900 mg/kg SCPart B: Infectivity Controls
Started66666716766
Received sc dose00000100000
Completed54566516666
Not completed12100200100
Withdrew: Move from study area-01000100000
Withdrew: Lost to follow-up00000100000
Withdrew: Withdrawal by subject10000000100
Withdrew: Other01100000000

Outcome measures

PrimaryNumber of Participants Reporting Solicited Adverse Events (AEs) in the Subcutaneous Cohorts

Solicited AEs were defined events participants were specifically asked about, which were recorded by participants in the memory aid card. Solicited AES included local injection site AEs (pain, redness, swelling, itching and bruising) and systemic AEs (fever, chills, headache, fatigue, nausea, muscle pain and joint pain). A Solicited AE does not necessarily have a causal relationship with the intervention.

Time frame:
Day 1 to Day 7 post dose
Reported as:
Count of participants · Participants
Number of Participants Reporting Solicited Adverse Events (AEs) in the Subcutaneous Cohorts
ParticipantsPart A (SAD Cohort 2): MAM01 5 mg/kg SCPart A (SAD Cohort 2): Repeat Dose MAM01 5 mg/kg SCPart A (SAD Cohort 3): Repeat Dose MAM01 5 mg/kg SCPart A: Placebo Then SC Repeat Dose MAM01 5 mg/kgPart B (Cohort 6, Group 1): MAM01 450 mg/kg SCPart B (Cohort 6, Group 2): MAM01 600 mg/kg SCPart B (Cohort 6, Group 3): MAM01 900 mg/kg SC
Any injection site symptom0020223
Any general body symptom1020112
PrimaryNumber of Participants Reporting Unsolicited Adverse Events

In this study an unsolicited AE is any AE not captured as a solicited AE in the Memory Aid Card between Day 0 and Day 7 after MAM01 dosing, and all AEs occurring after Day 7 post dose were collected as Unsolicited AEs.

Time frame:
Through Day 28 post dose
Reported as:
Count of participants · Participants
Number of Participants Reporting Unsolicited Adverse Events
ParticipantsPart A (SAD Cohort 1): MAM01 1.5 mg/kg IVPart A (SAD Cohort 2): MAM01 5 mg/kg SC (Repeat Dose 5 mg/kg SC)Part A (SAD Cohort 3): MAM01 5 mg/kg IV (Repeat Dose 5 mg/kg SC)Part A (SAD Cohort 4): MAM01 10 mg/kg IVPart A (SAD Cohort 5): MAM01 40 mg/kg IVPart A: PlaceboPart A: Infectivity ControlsPart B (Cohort 6, Group 1): MAM01 450 mg/kg SCPart B (Cohort 6, Group 2): MAM01 600 mg/kg SCPart B (Cohort 6, Group 3): MAM01 900 mg/kg SCPart B: Infectivity Controls
Number of Participants Reporting Unsolicited Adverse Events36444404253
PrimaryNumber of Participants Reporting Serious Adverse Events (SAEs) Including Suspected Unexpected Serious Adverse Reactions (SUSARs) and Adverse Events Special Interest (AESIs)

A SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect or is a medically significant / important event or reaction. SUSARs are AEs reported for a clinical trial participant, which is assessed by the Sponsor and or study investigator as being unexpected, serious and as having a reasonable possibility of a causal relationship with the study drug. AESIs are adverse events that the Sponsor wants to monitor closely and which require expedited reporting.

Time frame:
Up to Day 168
Reported as:
Count of participants · Participants
Number of Participants Reporting Serious Adverse Events (SAEs) Including Suspected Unexpected Serious Adverse Reactions (SUSARs) and Adverse Events Special Interest (AESIs)
ParticipantsPart A (SAD Cohort 1): MAM01 1.5 mg/kg IVPart A (SAD Cohort 2): MAM01 5 mg/kg SC (Repeat Dose 5 mg/kg SC)Part A (SAD Cohort 3): MAM01 5 mg/kg IV (Repeat Dose 5 mg/kg SC)Part A (SAD Cohort 4): MAM01 10 mg/kg IVPart A (SAD Cohort 5): MAM01 40 mg/kg IVPart A: PlaceboPart A: Infectivity ControlsPart B (Cohort 6, Group 1): MAM01 450 mg/kg SCPart B (Cohort 6, Group 2): MAM01 600 mg/kg SCPart B (Cohort 6, Group 3): MAM01 900 mg/kg SCPart B: Infectivity Controls
Any SAE01000000000
Any SUSAR00000000000
Any AESI00000000000
PrimaryNumber of Participants Who Received 2 Doses Reporting SUSARs, SAEs and AESIs

A SAE is defined as any untoward medical occurrence that, at any dose: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect or is a medically significant / important event or reaction. SUSARs are AEs reported for a clinical trial participant, which is assessed by the Sponsor and or study investigator as being unexpected, serious and as having a reasonable possibility of a causal relationship with the study drug. AESIs are adverse events that the Sponsor wants to monitor closely and which require expedited reporting.

Time frame:
Through Day 336
Reported as:
Count of participants · Participants
Number of Participants Who Received 2 Doses Reporting SUSARs, SAEs and AESIs
ParticipantsPart A (SAD Cohort 2): Repeat Dose MAM01 5 mg/kg SCPart A (SAD Cohort 3): Repeat Dose MAM01 5 mg/kg SC
Any SAE00
Any SUSAR00
Any AESI00
PrimaryNumber of Participants With Clinically Significant Changes in Serum Chemistry Parameters

Blood samples were collected for the assessment of alanine transaminase, aspartate aminotransferase, alkaline phosphatase, total carbon-dioxide (CO2), chloride, total bilirubin, creatinine, blood urea nitrogen, glucose, albumin, total protein, sodium and potassium.

Time frame:
Through Day 336
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Changes in Serum Chemistry Parameters
ParticipantsPart A (SAD Cohort 1): MAM01 1.5 mg/kg IVPart A (SAD Cohort 2): MAM01 5 mg/kg SC (Repeat Dose 5 mg/kg SC)Part A (SAD Cohort 3): MAM01 5 mg/kg IV (Repeat Dose 5 mg/kg SC)Part A (SAD Cohort 4): MAM01 10 mg/kg IVPart A (SAD Cohort 5): MAM01 40 mg/kg IVPart A: PlaceboPart A: Infectivity ControlsPart B (Cohort 6, Group 1): MAM01 450 mg/kg SCPart B (Cohort 6, Group 2): MAM01 600 mg/kg SCPart B (Cohort 6, Group 3): MAM01 900 mg/kg SCPart B: Infectivity Controls
Number of Participants With Clinically Significant Changes in Serum Chemistry Parameters00000000000
PrimaryNumber of Participants With Clinically Significant Changes in Hematology Parameters

Blood samples were collected for the assessment of complete blood count (CBC) including hemoglobin, platelet count, and white blood cell counts, and differential to include the absolute counts for neutrophils, lymphocytes, eosinophils, and monocytes.

Time frame:
Through Day 336
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Changes in Hematology Parameters
ParticipantsPart A (SAD Cohort 1): MAM01 1.5 mg/kg IVPart A (SAD Cohort 2): MAM01 5 mg/kg SC (Repeat Dose 5 mg/kg SC)Part A (SAD Cohort 3): MAM01 5 mg/kg IV (Repeat Dose 5 mg/kg SC)Part A (SAD Cohort 4): MAM01 10 mg/kg IVPart A (SAD Cohort 5): MAM01 40 mg/kg IVPart A: PlaceboPart A: Infectivity ControlsPart B (Cohort 6, Group 1): MAM01 450 mg/kg SCPart B (Cohort 6, Group 2): MAM01 600 mg/kg SCPart B (Cohort 6, Group 3): MAM01 900 mg/kg SCPart B: Infectivity Controls
Number of Participants With Clinically Significant Changes in Hematology Parameters00000000000
SecondaryMaximal Observed Concentration (Cmax) Following Single Dose of MAM01

Serum from venous blood samples was collected for measurement of MAM01 pharmacokinetics.

Time frame:
Pre-dose, Day 0: end of infusion (EOI), 1, 3 and 6 hours; Day 1: 24 hours; Day 2: 48 hours; Days 7, 14, 28, 42, 56, 70, 84, 98, 112, 140, 168, 224 and 280 post-dose
Reported as:
Geometric mean · micrograms per milliliter
Maximal Observed Concentration (Cmax) Following Single Dose of MAM01
micrograms per milliliterPart A (SAD Cohort 1): MAM01 1.5 mg/kg IVPart A (SAD Cohort 2): MAM01 5 mg/kg SCPart A (SAD Cohort 3): MAM01 5 mg/kg IVPart A (SAD Cohort 4): MAM01 10 mg/kg IVPart A (SAD Cohort 5): MAM01 40 mg/kg IVPart B (Cohort 6, Group 1): MAM01 450 mg/kg SCPart B (Cohort 6, Group 2): MAM01 600 mg/kg SCPart B (Cohort 6, Group 3): MAM01 900 mg/kg SC
Maximal Observed Concentration (Cmax) Following Single Dose of MAM0119.5 ± 13.933.1 ± 30.858.1 ± 8.6122 ± 15.7513 ± 10.046.0 ± 18.562.7 ± 8.495.6 ± 25.6
SecondaryCmax Following Repeat Dosing of MAM01

Serum from venous blood samples was collected for measurement of MAM01 pharmacokinetics.

Time frame:
Pre-dose, Day 0: end of infusion (EOI), 1, 3 and 6 hours, Day 1: 24 hours, Day 2: 48 hours, Days 7, 14, 28, 42, 56, 70, 84, 98, 112, 140, 168, 224 and 280 post-dose
Reported as:
Geometric mean · micrograms per milliliter
Cmax Following Repeat Dosing of MAM01
micrograms per milliliterPart A (SAD Cohort 2): Repeat Dose MAM01 5 mg/kg SCPart A (SAD Cohort 3): Repeat Dose MAM01 5 mg/kg SC
Cmax Following Repeat Dosing of MAM0142.8 ± 4.240.4 ± 9.0
SecondaryArea Under the Curve (AUC) From Time=0 to the Last Measurable Concentration (AUC0-t) Following Single Dose of MAM01

Serum from venous blood samples was collected for measurement of MAM01 pharmacokinetics.

Time frame:
Pre-dose, Day 0: end of infusion (EOI), 1, 3 and 6 hours; Day 1: 24 hours; Day 2: 48 hours; Days 7, 14, 28, 42, 56, 70, 84, 98, 112, 140, 168, 224 and 280 post-dose
Reported as:
Geometric mean · day*micrograms per milliliter
Area Under the Curve (AUC) From Time=0 to the Last Measurable Concentration (AUC0-t) Following Single Dose of MAM01
day*micrograms per milliliterPart A (SAD Cohort 1): MAM01 1.5 mg/kg IVPart A (SAD Cohort 2): MAM01 5 mg/kg SCPart A (SAD Cohort 3): MAM01 5 mg/kg IVPart A (SAD Cohort 4): MAM01 10 mg/kg IVPart A (SAD Cohort 5): MAM01 40 mg/kg IVPart B (Cohort 6, Group 1): MAM01 450 mg/kg SCPart B (Cohort 6, Group 2): MAM01 600 mg/kg SCPart B (Cohort 6, Group 3): MAM01 900 mg/kg SC
Area Under the Curve (AUC) From Time=0 to the Last Measurable Concentration (AUC0-t) Following Single Dose of MAM011448.7 ± 22.63154.5 ± 35.15054.9 ± 18.110997.7 ± 17.543082.1 ± 14.72734.4 ± 24.03408.6 ± 31.76018.7 ± 22.0
SecondaryAUC (0-t) Following Repeat Dosing of MAM01

Serum from venous blood samples was collected for measurement of MAM01 pharmacokinetics.

Time frame:
Pre-dose, Day 0: end of infusion (EOI), 1, 3 and 6 hours; Day 1: 24 hours; Day 2: 48 hours; Days 7, 14, 28, 42, 56, 70, 84, 98, 112, 140, 168, 224 and 280 post-dose
Reported as:
Geometric mean · day*micrograms per milliliter
AUC (0-t) Following Repeat Dosing of MAM01
day*micrograms per milliliterPart A (SAD Cohort 2): Repeat Dose MAM01 5 mg/kg SCPart A (SAD Cohort 3): Repeat Dose MAM01 5 mg/kg SC
AUC (0-t) Following Repeat Dosing of MAM014008.3 ± 14.84082.9 ± 15.7
SecondaryPartial AUC's Time= 0 to the CHMI Challenge (AUC0-CHMI) of MAM01

Serum from venous blood samples was collected for measurement of MAM01 pharmacokinetics.

Time frame:
Pre-dose, Day 0: end of infusion (EOI), 1, 3 and 6 hours; Day 1: 24 hours; Day 2: 48 hours; Days 7, 14, 28, 42, 56, 70, 84, 98, 112, 140, 168, 224 and 280 post-dose
Reported as:
Geometric mean · day*micrograms per milliliter
Partial AUC's Time= 0 to the CHMI Challenge (AUC0-CHMI) of MAM01
day*micrograms per milliliterPart A (SAD Cohort 1): MAM01 1.5 mg/kg IVPart A (SAD Cohort 2): MAM01 5 mg/kg SCPart A (SAD Cohort 3): MAM01 5 mg/kg IVPart A (SAD Cohort 4): MAM01 10 mg/kg IVPart A (SAD Cohort 5): MAM01 40 mg/kg IVPart B (Cohort 6, Group 1): MAM01 450 mg/kg SCPart B (Cohort 6, Group 2): MAM01 600 mg/kg SCPart B (Cohort 6, Group 3): MAM01 900 mg/kg SC
Partial AUC's Time= 0 to the CHMI Challenge (AUC0-CHMI) of MAM011481.4 ± 10.02962.8 ± 32.04503.9 ± 18.09197.7 ± 17.131934.1 ± 15.11323.4 ± 18.91658.4 ± 15.62771.4 ± 23.2
SecondaryConcentration at the Time of CHMI (CCHMI) of MAM01

Serum from venous blood samples was collected for measurement of MAM01 pharmacokinetics.

Time frame:
Pre-dose, Day 0: end of infusion (EOI), 1, 3 and 6 hours; Day 1: 24 hours; Day 2: 48 hours; Days 7, 14, 28, 42, 56, 70, 84, 98, 112, 140, 168, 224 and 280 post-dose
Reported as:
Geometric mean · micrograms per milliliter
Concentration at the Time of CHMI (CCHMI) of MAM01
micrograms per milliliterPart A (SAD Cohort 1): MAM01 1.5 mg/kg IVPart A (SAD Cohort 2): MAM01 5 mg/kg SCPart A (SAD Cohort 3): MAM01 5 mg/kg IVPart A (SAD Cohort 4): MAM01 10 mg/kg IVPart A (SAD Cohort 5): MAM01 40 mg/kg IVPart B (Cohort 6, Group 1): MAM01 450 mg/kg SCPart B (Cohort 6, Group 2): MAM01 600 mg/kg SCPart B (Cohort 6, Group 3): MAM01 900 mg/kg SC
Concentration at the Time of CHMI (CCHMI) of MAM013.02 ± 15.47.00 ± 39.413.2 ± 34.931.2 ± 23.3119 ± 30.836.0 ± 18.340.3 ± 45.477.3 ± 20.4
SecondaryBlood Terminal Elimination Rate Constant (λz) of MAM01

Serum from venous blood samples was collected for measurement of MAM01 pharmacokinetics.

Time frame:
Pre-dose, Day 0: end of infusion (EOI), 1, 3 and 6 hours; Day 1: 24 hours; Day 2: 48 hours; Days 7, 14, 28, 42, 56, 70, 84, 98, 112, 140, 168, 224 and 280 post-dose
Reported as:
Geometric mean · 1/day
Blood Terminal Elimination Rate Constant (λz) of MAM01
1/dayPart A (SAD Cohort 1): MAM01 1.5 mg/kg IVPart A (SAD Cohort 2): MAM01 5 mg/kg SCPart A (SAD Cohort 3): MAM01 5 mg/kg IVPart A (SAD Cohort 4): MAM01 10 mg/kg IVPart A (SAD Cohort 5): MAM01 40 mg/kg IVPart B (Cohort 6, Group 1): MAM01 450 mg/kg SCPart B (Cohort 6, Group 2): MAM01 600 mg/kg SCPart B (Cohort 6, Group 3): MAM01 900 mg/kg SC
Blood Terminal Elimination Rate Constant (λz) of MAM01NA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NANA ± NA
SecondaryTerminal Half Life (t1/2) Following Single Dose of MAM01

Serum from venous blood samples was collected for measurement of MAM01 pharmacokinetics.

Time frame:
Time Frame: Pre-dose, Day 0: end of infusion (EOI), 1, 3 and 6 hours; Day 1: 24 hours; Day 2: 48 hours; Days 7, 14, 28, 42, 56, 70, 84, 98, 112, 140, 168, 224 and 280 post-dose
Reported as:
Geometric mean · Days
Terminal Half Life (t1/2) Following Single Dose of MAM01
DaysPart A (SAD Cohort 1): MAM01 1.5 mg/kg IVPart A (SAD Cohort 2): MAM01 5 mg/kg SCPart A (SAD Cohort 3): MAM01 5 mg/kg IVPart A (SAD Cohort 4): MAM01 10 mg/kg IVPart A (SAD Cohort 5): MAM01 40 mg/kg IVPart B (Cohort 6, Group 1): MAM01 450 mg/kg SCPart B (Cohort 6, Group 2): MAM01 600 mg/kg SCPart B (Cohort 6, Group 3): MAM01 900 mg/kg SC
Terminal Half Life (t1/2) Following Single Dose of MAM0170.7 ± 9.368.1 ± 14.974.3 ± 15.570.7 ± 12.571.7 ± 17.0—NA ± NA—
Secondaryt1/2 Following Repeat Dosing of MAM01

Serum from venous blood samples was collected for measurement of MAM01 pharmacokinetics.

Time frame:
Pre-dose, Day 0: end of infusion (EOI), 1, 3 and 6 hours; Day 1: 24 hours; Day 2: 48 hours; Days 7, 14, 28, 42, 56, 70, 84, 98, 112, 140, 168, 224 and 280 post-dose
Reported as:
Geometric mean · Days
t1/2 Following Repeat Dosing of MAM01
DaysPart A (SAD Cohort 2): Repeat Dose MAM01 5 mg/kg SCPart A (SAD Cohort 3): Repeat Dose MAM01 5 mg/kg SC
t1/2 Following Repeat Dosing of MAM0167.2 ± 0.456.0 ± 3.0
SecondaryAUC From Time=0 Extrapolated to Infinity (AUC0-infinity) of MAM01

Serum from venous blood samples was collected for measurement of MAM01 pharmacokinetics.

Time frame:
Pre-dose, Day 0: end of infusion (EOI), 1, 3 and 6 hours; Day 1: 24 hours; Day 2: 48 hours; Days 7, 14, 28, 42, 56, 70, 84, 98, 112, 140, 168, 224 and 280 post-dose
Reported as:
Geometric mean · day*micrograms per milliliter
AUC From Time=0 Extrapolated to Infinity (AUC0-infinity) of MAM01
day*micrograms per milliliterPart A (SAD Cohort 1): MAM01 1.5 mg/kg IVPart A (SAD Cohort 2): MAM01 5 mg/kg SCPart A (SAD Cohort 3): MAM01 5 mg/kg IVPart A (SAD Cohort 4): MAM01 10 mg/kg IVPart A (SAD Cohort 5): MAM01 40 mg/kg IVPart B (Cohort 6, Group 1): MAM01 450 mg/kg SCPart B (Cohort 6, Group 2): MAM01 600 mg/kg SCPart B (Cohort 6, Group 3): MAM01 900 mg/kg SC
AUC From Time=0 Extrapolated to Infinity (AUC0-infinity) of MAM011781 ± 10.83738 ± 38.65335 ± 20.012467 ± 19.249011 ± 17.7—NA ± NA—
SecondaryAbsolute Bioavailability of SC Formulation Following Repeated Dosing of MAM01

Serum from venous blood samples was collected for measurement of MAM01 pharmacokinetics.

Time frame:
Pre-dose, Day 0: end of infusion (EOI), 1, 3 and 6 hours; Day 1: 24 hours; Day 2: 48 hours; Days 7, 14, 28, 42, 56, 70, 84, 98, 112, 140, 168, 224, 280 and 378 post-dose
Reported as:
Geometric mean · Unitless
Absolute Bioavailability of SC Formulation Following Repeated Dosing of MAM01
UnitlessPart A (SAD Cohort 2): Repeat Dose MAM01 5 mg/kg SCPart A (SAD Cohort 3): Repeat Dose MAM01 5 mg/kg SC
Absolute Bioavailability of SC Formulation Following Repeated Dosing of MAM01NA ± NA0.692 ± 13.6
SecondaryAccumulation Ratio (AUC0-168) Following Repeated Doses of MAM01

Serum from venous blood samples was collected for measurement of MAM01 pharmacokinetics. The accumulation ratio was calculated as the ratio of AUC (0-168) (post first dose) to AUC (210-378) (post redose).

Time frame:
Pre-dose, Day 0: end of infusion (EOI), 1, 3 and 6 hours; Day 1: 24 hours; Day 2: 48 hours; Days 7, 14, 28, 42, 56, 70, 84, 98, 112, 140 and 168 post-dose
Reported as:
Geometric mean · Ratio
Accumulation Ratio (AUC0-168) Following Repeated Doses of MAM01
RatioPart A (SAD Cohort 2): Repeat Dose MAM01 5 mg/kg SCPart A (SAD Cohort 3): Repeat Dose MAM01 5 mg/kg SC
Accumulation Ratio (AUC0-168) Following Repeated Doses of MAM011.29 ± 15.7NA ± NA
SecondaryNumber of Participants With Confirmed Pf Infection Assessed by Quantitative Polymerase Chain Reaction Assay (qRT-PCR) After CHMI

The characterization of protective efficacy against Pf following CHMI challenge, was assessed by evaluating the presence or absence of Pf infection as determined by qRT-PCR after CHMI (planned through 4 weeks post-CHMI) and evaluating the time to parasitemia after CHMI in each cohort.

Time frame:
Up to Day 27 post-CHMI
Reported as:
Count of participants · Participants
Number of Participants With Confirmed Pf Infection Assessed by Quantitative Polymerase Chain Reaction Assay (qRT-PCR) After CHMI
ParticipantsPart A (SAD Cohort 1): MAM01 1.5 mg/kg IVPart A (SAD Cohort 2): MAM01 5 mg/kg SC (Repeat Dose 5 mg/kg SC)Part A (SAD Cohort 3): MAM01 5 mg/kg IV (Repeat Dose 5 mg/kg SC)Part A (SAD Cohort 4): MAM01 10 mg/kg IVPart A (SAD Cohort 5): MAM01 40 mg/kg IVPart A: PlaceboPart A: Infectivity ControlsPart B (Cohort 6, Group 1): MAM01 450 mg/kg SCPart B (Cohort 6, Group 2): MAM01 600 mg/kg SCPart B (Cohort 6, Group 3): MAM01 900 mg/kg SCPart B: Infectivity Controls
Number of Participants With Confirmed Pf Infection Assessed by Quantitative Polymerase Chain Reaction Assay (qRT-PCR) After CHMI35550514646
SecondaryTime to Parasitemia After CHMI

Parasitemia was assessed by qRT-PCR up to Day 27 following CHMI. In addition, a thick blood smear was prepared for microscopic analysis, which was examined only once the first qRT-PCR sample tested positive. Daily parasitemia monitoring continued until the participant had a confirmed initial positive qRT-PCR. The first positive qRT-PCR triggered either a second PCR test or microscopic analysis of the blood smear. Once two positive results were obtained, rescue therapy was initiated.

Time frame:
Up to Day 27 post-CHMI
Reported as:
Median · Days
Time to Parasitemia After CHMI
DaysPart A (SAD Cohort 1): MAM01 1.5 mg/kg IVPart A (SAD Cohort 2): MAM01 5 mg/kg SC (Repeat Dose 5 mg/kg SC)Part A (SAD Cohort 3): MAM01 5 mg/kg IV (Repeat Dose 5 mg/kg SC)Part A (SAD Cohort 4): MAM01 10 mg/kg IVPart A (SAD Cohort 5): MAM01 40 mg/kg IVPart A: PlaceboPart A: Infectivity ControlsPart B (Cohort 6, Group 1): MAM01 450 mg/kg SCPart B (Cohort 6, Group 2): MAM01 600 mg/kg SCPart B (Cohort 6, Group 3): MAM01 900 mg/kg SCPart B: Infectivity Controls
Time to Parasitemia After CHMI9 (7 to 11)7 (7 to 10)9 (9 to 11)10 (8 to 11)NA (NA to NA)7 (7 to 7)7 (NA to NA)9 (7 to NA)8 (NA to NA)9.5 (9 to NA)7 (NA to NA)
SecondaryCohorts 1, 4 and 5: Numbers of Participants With Seroconversion

The formation of ADAs (immunogenicity) following MAM01 SC and/or IV administration) was evaluated by measuring titers of ADA to MAM01 to last study visit for all participants. Capillary blood samples and selected serum samples were collected on volumetric absorptive micro-sampling (VAMS) devices at timepoints.

Time frame:
Up to Day 280
Reported as:
Count of participants · Participants
Cohorts 1, 4 and 5: Numbers of Participants With Seroconversion
ParticipantsPart A (SAD Cohort 1): MAM01 1.5 mg/kg IVPart A (SAD Cohort 4): MAM01 10 mg/kg IVPart A (SAD Cohort 5): MAM01 40 mg/kg IV
Cohorts 1, 4 and 5: Numbers of Participants With Seroconversion000
SecondaryCohorts 2 and 3: Numbers of Participants Receiving 2 Doses With Seroconversion

The formation of ADAs (immunogenicity) following MAM01 SC and/or IV administration) was evaluated by measuring titers of ADA to MAM01 to last study visit for all participants. Capillary blood samples and selected serum samples were collected on volumetric absorptive micro-sampling (VAMS) devices at timepoints.

Time frame:
Up to Day 378
Reported as:
Count of participants · Participants
Cohorts 2 and 3: Numbers of Participants Receiving 2 Doses With Seroconversion
ParticipantsPart A (SAD Cohort 2): MAM01 5 mg/kg SC (Repeat Dose 5 mg/kg SC)Part A (SAD Cohort 3): MAM01 5 mg/kg IV (Repeat Dose 5 mg/kg SC)
Cohorts 2 and 3: Numbers of Participants Receiving 2 Doses With Seroconversion00
SecondaryCohort 6: Numbers of Participants With Seroconversion

The formation of ADAs (immunogenicity) following MAM01 SC and/or IV administration) was evaluated by measuring titers of ADA to MAM01 to last study visit for all participants. Capillary blood samples and selected serum samples were collected on volumetric absorptive micro-sampling (VAMS) devices at timepoints.

Time frame:
Up to Day 84
Reported as:
Count of participants · Participants
Cohort 6: Numbers of Participants With Seroconversion
ParticipantsPart B (Cohort 6, Group 1): MAM01 450 mg/kg SCPart B (Cohort 6, Group 2): MAM01 600 mg/kg SCPart B (Cohort 6, Group 3): MAM01 900 mg/kg SC
Cohort 6: Numbers of Participants With Seroconversion000

Adverse events

Collected over Solicited AEs collected daily from Day 1 to Day 7 post dose (included injection site pain, redness, swelling, itching, bruising, fever, chills, headache, fatigue, nausea, muscle pain and joint pain) Unsolicited AEs were collected for 28 days after each dose. SAEs were collected from Screening through End of Study (Day 378 for Part A and Day 84 for Part B).. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part A (SAD Cohort 1): MAM01 1.5 mg/kg IV0/6 (0%)0/6 (0%)3/6 (50%)
Part A (SAD Cohort 2): MAM01 5 mg/kg SC (Repeat Dose 5 mg/kg SC)0/6 (0%)1/6 (16.7%)6/6 (100%)
Part A (SAD Cohort 3): MAM01 5 mg/kg IV (Repeat Dose 5 mg/kg SC)0/6 (0%)0/6 (0%)4/6 (66.7%)
Part A (SAD Cohort 4): MAM01 10 mg/kg IV0/6 (0%)0/6 (0%)4/6 (66.7%)
Part A (SAD Cohort 5): MAM01 40 mg/kg IV0/6 (0%)0/6 (0%)4/6 (66.7%)
Part A: Placebo0/7 (0%)0/7 (0%)4/7 (57.1%)
Part A: Infectivity Controls0/1 (0%)0/1 (0%)0/1 (0%)
Part B (Cohort 6, Group 1): MAM01 450 mg/kg SC0/6 (0%)0/6 (0%)4/6 (66.7%)
Part B (Cohort 6, Group 2): MAM01 600 mg/kg SC0/6 (0%)0/6 (0%)2/6 (33.3%)
Part B (Cohort 6, Group 3): MAM01 900 mg/kg SC0/6 (0%)0/6 (0%)5/6 (83.3%)
Part B: Infectivity Controls0/6 (0%)0/6 (0%)3/6 (50%)
Most frequent serious events
Most frequent serious events
EventPart A (SAD Cohort 1): MAM01 1.5 mg/kg IVPart A (SAD Cohort 2): MAM01 5 mg/kg SC (Repeat Dose 5 mg/kg SC)Part A (SAD Cohort 3): MAM01 5 mg/kg IV (Repeat Dose 5 mg/kg SC)Part A (SAD Cohort 4): MAM01 10 mg/kg IVPart A (SAD Cohort 5): MAM01 40 mg/kg IVPart A: PlaceboPart A: Infectivity ControlsPart B (Cohort 6, Group 1): MAM01 450 mg/kg SCPart B (Cohort 6, Group 2): MAM01 600 mg/kg SCPart B (Cohort 6, Group 3): MAM01 900 mg/kg SCPart B: Infectivity Controls
Depression suicidalPsychiatric disorders0/61/60/60/60/60/70/10/60/60/60/6
Most frequent other events
Showing 10 of 48
Most frequent other events
EventPart A (SAD Cohort 1): MAM01 1.5 mg/kg IVPart A (SAD Cohort 2): MAM01 5 mg/kg SC (Repeat Dose 5 mg/kg SC)Part A (SAD Cohort 3): MAM01 5 mg/kg IV (Repeat Dose 5 mg/kg SC)Part A (SAD Cohort 4): MAM01 10 mg/kg IVPart A (SAD Cohort 5): MAM01 40 mg/kg IVPart A: PlaceboPart A: Infectivity ControlsPart B (Cohort 6, Group 1): MAM01 450 mg/kg SCPart B (Cohort 6, Group 2): MAM01 600 mg/kg SCPart B (Cohort 6, Group 3): MAM01 900 mg/kg SCPart B: Infectivity Controls
Injection site painGeneral disorders0/60/60/60/60/60/70/11/62/61/60/6
Injection site rednessGeneral disorders0/60/60/60/60/60/70/11/60/62/60/6
Injection site bruisingGeneral disorders0/60/62/60/60/60/70/10/61/61/60/6
Respiratory tract infection viralInfections and infestations1/62/61/60/61/60/70/10/60/60/60/6
Upper respiratory tract infectionInfections and infestations0/60/60/61/60/60/70/10/60/62/60/6
HeadacheNervous system disorders0/60/60/60/60/60/70/11/60/61/62/6
HeadacheNervous system disorders1/61/62/61/62/62/70/11/61/61/60/6
Muscle painMusculoskeletal and connective tissue disorders1/61/61/60/61/61/70/11/60/62/60/6
FatigueGeneral disorders0/61/61/61/61/62/70/11/61/61/60/6
LymphadenopathyBlood and lymphatic system disorders0/61/60/60/60/60/70/11/60/60/60/6

Baseline characteristics

Safety Population comprised of all participants who were randomly assigned to a trial intervention and received the intervention, and the untreated infectivity control participants. One participant in Cohort 6 Group 2: MAM01 600 mg/kg discontinued from the trial (withdrew consent) prior to dosing.

Age, Continuous
Age, Continuous(Years)Part A (SAD Cohort 1): MAM01 1.5 mg/kg IVPart A (SAD Cohort 2): MAM01 5 mg/kg SC (Repeat Dose 5 mg/kg SC)Part A (SAD Cohort 3): MAM01 5 mg/kg IV (Repeat Dose 5 mg/kg SC)Part A (SAD Cohort 4): MAM01 10 mg/kg IVPart A (SAD Cohort 5): MAM01 40 mg/kg IVPart A: PlaceboPart A: Infectivity ControlsPart B (Cohort 6, Group 1): MAM01 450 mg/kg SCPart B (Cohort 6, Group 2): MAM01 600 mg/kg SCPart B (Cohort 6, Group 3): MAM01 900 mg/kg SCPart B: Infectivity ControlsTotal
Mean28.5 ± 4.2826.8 ± 7.0835.3 ± 7.5832.7 ± 8.5532.3 ± 8.1929.1 ± 7.2927.0 ± NA36.5 ± 10.3738.0 ± 8.4431.8 ± 5.9132.8 ± 8.1832.7 ± 7.76
Sex: Female, Male
Sex: Female, Male(Participants)Part A (SAD Cohort 1): MAM01 1.5 mg/kg IVPart A (SAD Cohort 2): MAM01 5 mg/kg SC (Repeat Dose 5 mg/kg SC)Part A (SAD Cohort 3): MAM01 5 mg/kg IV (Repeat Dose 5 mg/kg SC)Part A (SAD Cohort 4): MAM01 10 mg/kg IVPart A (SAD Cohort 5): MAM01 40 mg/kg IVPart A: PlaceboPart A: Infectivity ControlsPart B (Cohort 6, Group 1): MAM01 450 mg/kg SCPart B (Cohort 6, Group 2): MAM01 600 mg/kg SCPart B (Cohort 6, Group 3): MAM01 900 mg/kg SCPart B: Infectivity ControlsTotal
Female2334521512331
Male4332150154331
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Part A (SAD Cohort 1): MAM01 1.5 mg/kg IVPart A (SAD Cohort 2): MAM01 5 mg/kg SC (Repeat Dose 5 mg/kg SC)Part A (SAD Cohort 3): MAM01 5 mg/kg IV (Repeat Dose 5 mg/kg SC)Part A (SAD Cohort 4): MAM01 10 mg/kg IVPart A (SAD Cohort 5): MAM01 40 mg/kg IVPart A: PlaceboPart A: Infectivity ControlsPart B (Cohort 6, Group 1): MAM01 450 mg/kg SCPart B (Cohort 6, Group 2): MAM01 600 mg/kg SCPart B (Cohort 6, Group 3): MAM01 900 mg/kg SCPart B: Infectivity ControlsTotal
Hispanic or Latino011100020005
Not Hispanic or Latino6555671466657
Unknown or Not Reported000000000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Part A (SAD Cohort 1): MAM01 1.5 mg/kg IVPart A (SAD Cohort 2): MAM01 5 mg/kg SC (Repeat Dose 5 mg/kg SC)Part A (SAD Cohort 3): MAM01 5 mg/kg IV (Repeat Dose 5 mg/kg SC)Part A (SAD Cohort 4): MAM01 10 mg/kg IVPart A (SAD Cohort 5): MAM01 40 mg/kg IVPart A: PlaceboPart A: Infectivity ControlsPart B (Cohort 6, Group 1): MAM01 450 mg/kg SCPart B (Cohort 6, Group 2): MAM01 600 mg/kg SCPart B (Cohort 6, Group 3): MAM01 900 mg/kg SCPart B: Infectivity ControlsTotal
American Indian or Alaska Native000000000000
Asian1120110400010
Native Hawaiian or Other Pacific Islander000000000000
Black or African American2000200031311
White2336161135334
More than one race121020000006
Unknown or Not Reported000000010001
08

Study locations

1 site
  • Center for Vaccine Development and Global Health, 685 W. Baltimore Street
    Baltimore, Maryland 21201, United States
09

References and documents

Publications

  • Lyke KE, Berry AA, Laurens MB, Winkler J, Joshi S, Koudjra AR, Butler L, Billingsley PF, Pascini T, Patil A, Sim BKL, Fitzgerald G, Riegel J, Andrews K, Levi M, Anderson AB, Wells CD, Liu H, Huleatt J, Miller RS. Human monoclonal antibody MAM01 for protection against malaria in adults in the USA: a first-in-human, phase 1, dose-escalation, double-blind, placebo-controlled, adaptive trial. Lancet Infect Dis. 2026 Feb;26(2):170-181. doi: 10.1016/S1473-3099(25)00481-5. Epub 2025 Sep 23. PubMed 41005346 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2023 to primary completion in Dec 2024, 15 months.

Results were first posted in Jun 2026, 1 year 5 months after primary completion.

Of 64 non-industry phase 1 interventional studies under Malaria, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 24. This study's 15 months is above that.

Counting every sponsor, half of 93 studies reached it within 13 months; a quarter within 7 and three quarters within 20.

How these figures are worked out, and which studies are left out of them.

Registered
May 26, 2023
First posted
Jun 6, 2023
StartActual
Aug 14, 2023
Primary completionActual
Dec 13, 2024
CompletionActual
Dec 13, 2024
Results first posted
Jun 12, 2026
Last update
Jun 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05891236
Lead sponsor
Gates Medical Research Institute
Responsible party
Sponsor
First posted
Jun 6, 2023
Start date
Aug 14, 2023
Primary completion
Dec 13, 2024
Completion
Dec 13, 2024
Results posted
Jun 12, 2026
Last update
Jun 12, 2026

Study contacts

+1 866 789 5767
study director · Gates Medical Research Institute

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion